Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Biotechnology, Inc. | LinkedIn
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Pharma (@PumaPharma) / Twitter
puma pharmaceuticals stock price Off 54% - canerofset.com
ICOMPRE 2 DE CADA CAJA puma biotechnology inc Y OBTENGA UN 70% DE DESCUENTO!
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Puma Biotechnology
PBYI Institutional Ownership - Puma Biotechnology Inc Stock
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire
Puma Biotechnology
Puma catches fifth approval, hunts new indication for Nerlynx
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology - Crunchbase Company Profile & Funding
